medicinova
announces
biocomo
intranasal
rs
virus
vaccine
successfully
induced
neutralizing
antibodies
rs
virus
mice
using
technology
la
jolla
globe
newswire
medicinova
biopharmaceutical
company
traded
nasdaq
global
market
nasdaq
mnov
jasdaq
market
tokyo
stock
exchange
code
number
today
announced
biocomo
medicinova
vaccine
announced
respiratory
syncytial
rs
virus
vaccine
using
technology
induced
high
neutralizing
antibodies
mice
biocomo
issued
press
release
september
biocomo
rs
virus
vaccine
created
using
platform
technology
developed
biocomo
mie
university
rs
virus
specific
antigen
loaded
mice
inoculated
intranasal
administration
strong
induction
neutralizing
antibodies
prefusion
f
antigen
confirmed
rs
virus
known
infect
human
respiratory
tract
occurs
throughout
life
general
rs
virus
cause
mild
cold
symptoms
healthy
adults
however
infants
infection
immunocompromised
people
elderly
people
may
develop
severe
diseases
bronchitis
bronchiolitis
pneumonia
rs
virus
vaccine
development
ongoing
past
years
without
success
date
successful
induction
neutralizing
antibodies
rs
virus
using
technology
intranasal
route
administration
support
scientific
technical
rationale
medicinova
intranasal
vaccine
confirmation
neutralizing
antibody
induction
rs
virus
vaccine
strongly
supports
likelihood
successful
induction
neutralizing
antibodies
medicinova
intranasal
vaccine
also
uses
technology
biocomo
rs
virus
vaccine
mouse
model
study
conducted
fraunhofer
institute
cell
therapy
immunology
izi
leipzig
germany
izi
largest
research
development
institute
field
medicine
life
sciences
eu
medicinova
also
planning
work
izi
additional
animal
studies
vaccine
development
yuichi
iwaki
president
chief
executive
officer
medicinova
commented
pleased
confirm
intranasal
vaccine
using
technology
induces
neutralizing
antibodies
demonstrated
biocomo
rs
virus
vaccine
look
forward
reporting
additional
progress
intranasal
vaccine
using
soon
vaccine
innovative
viral
vector
biocomo
mie
university
derived
recombinant
human
parainfluenza
virus
type
highly
efficient
ability
transfer
multiple
foreign
proteins
recipients
strong
safety
profile
secondary
infectious
virus
produced
designed
display
gene
also
foreign
protein
surface
inside
viral
membrane
therefore
carry
large
membrane
proteins
viruses
signal
transduction
receptors
ligand
proteins
viral
surface
able
carry
proteins
require
proper
structure
multimeric
structure
maintaining
structure
elicits
good
immunogenicity
antigen
proteins
without
adjuvants
vaccine
prototype
developed
include
specific
antigen
protein
order
express
maximum
antigenicity
vaccine
developed
intranasal
vaccine
addition
intramuscular
injection
high
affinity
nasal
upper
respiratory
tract
mucosa
route
natural
infection
intranasal
vaccine
expected
induce
local
mucosal
immunity
date
biocomo
succeeded
producing
recombinant
ebola
virus
vaccine
https
articles
respiratory
syncytial
virus
prefusion
f
vaccine
unpublished
data
using
platform
technology
biocomo
biocomo
biotech
company
founded
mie
prefecture
japan
may
developing
technology
platforms
creating
novel
predominant
vaccine
carriers
adjuvants
enhance
immunity
collaboration
microbiology
molecular
genetics
department
mie
university
already
succeeded
development
highly
efficacious
art
vaccine
carrier
novel
adjuvant
candidates
technology
applied
production
next
generation
vaccines
prevention
infections
rs
virus
ebola
virus
influenza
virus
also
enable
faster
production
vaccines
core
platform
technology
carries
corporate
namesake
biocomo
leading
vaccine
carrier
derived
recombinant
human
parainfluenza
virus
vectors
biocomo
dedicated
inventing
new
vaccines
global
infection
threats
well
malignant
tumors
medicinova
medicinova
publicly
traded
biopharmaceutical
company
founded
upon
acquiring
developing
novel
therapeutics
treatment
diseases
unmet
medical
needs
primary
commercial
focus
market
medicinova
current
strategy
focus
vaccine
ibudilast
neurological
disorders
progressive
multiple
sclerosis
ms
amyotrophic
lateral
sclerosis
als
substance
dependence
alcohol
use
disorder
methamphetamine
dependence
opioid
dependence
well
prevention
acute
respiratory
distress
syndrome
ards
caused
tipelukast
fibrotic
diseases
nonalcoholic
steatohepatitis
nash
idiopathic
pulmonary
fibrosis
ipf
medicinova
pipeline
also
includes
bedoradrine
treatment
acute
exacerbations
asthma
denibulin
solid
tumor
cancers
medicinova
engaged
strategic
partnering
potential
funding
discussions
support
development
programs
information
medicinova
please
visit
statements
press
release
historical
nature
constitute
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
include
without
limitation
statements
regarding
future
development
efficacy
vaccine
statements
may
preceded
followed
otherwise
include
words
believes
expects
anticipates
intends
estimates
projects
could
may
would
considering
planning
similar
expressions
statements
involve
number
risks
uncertainties
may
cause
actual
results
events
differ
materially
expressed
implied
statements
factors
may
cause
actual
results
events
differ
materially
expressed
implied
statements
include
limited
risks
obtaining
future
partner
grant
funding
development
vaccine
risks
raising
sufficient
capital
needed
fund
medicinova
operations
contribution
clinical
development
risks
uncertainties
inherent
clinical
trials
including
potential
cost
expected
timing
risks
associated
clinical
trials
designed
meet
fda
guidance
viability
development
considering
factors
product
development
commercialization
risks
uncertainty
whether
results
clinical
trials
predictive
results
later
stages
product
development
risk
delays
failure
obtain
maintain
regulatory
approval
risks
associated
reliance
third
parties
sponsor
fund
clinical
trials
risks
regarding
intellectual
property
rights
product
candidates
ability
defend
enforce
intellectual
property
rights
risk
failure
third
parties
upon
medicinova
relies
conduct
clinical
trials
manufacture
product
candidates
perform
expected
risk
increased
cost
delays
due
delays
commencement
enrollment
completion
analysis
clinical
trials
significant
issues
regarding
adequacy
clinical
trial
designs
execution
clinical
trials
timing
expected
filings
regulatory
authorities
medicinova
collaborations
third
parties
availability
funds
complete
product
development
plans
medicinova
ability
obtain
third
party
funding
programs
raise
sufficient
capital
needed
risks
uncertainties
described
medicinova
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
periodic
reports
form
current
reports
form
undue
reliance
placed
statements
speak
date
hereof
medicinova
disclaims
intent
obligation
revise
update
statements
